Avid Bioservices, Inc. (NASDAQ:CDMO) headquartered in Tustin, will host a conference call for the investment community to discuss the 1Q21 financial results on 1st September 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website edge.media-server.com/mmc/p/64ateurd
To participate on the live call, please dial (877) 312-5443 Toll Free or (253) 237-1126 Toll Number
Earnings Expectation
Avid Bioservices, Inc. is set to announce first quarter earning results on Tuesday 1st September 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, CDMO to report 1Q21 loss of $ 0.07 per share from revenue of $ 16.50 million. For the full year, analysts anticipate top line of $ 78.96 million, while looking forward to loss of $ 0.11 per share bottom line.
The Company Outlook
Full Year 2021 topline are forecasted in a range of$ 76.00 million ~ $ 81.00 million
Click Here For More Historical Outlooks Of Avid Bioservices, Inc.
Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support.
